Erasca
ERAS----
Erasca (ERAS)
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Erasca Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
$22.8019.31%
Forecast & RatingBuy
10analysts
- Strong buy60.00%
- Buy20.00%
- Hold20.00%
- Sell0.00%
- Strong sell0.00%
News
- prnewswire · 20 hours ago
15:31 ETErasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- PR Newswire · 2 days ago, 09:07 AM
Lost Money on Erasca, Inc. (ERAS)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
- prnewswire · 2 days ago, 11:26 AM
12:26 ETNASDAQ: ERAS CLASS ACTION NOTICE: Berger Montague Encourages Erasca, Inc. (NASDAQ: ERAS) Investors to Inquire About a Securities Fraud Class Action
- prnewswire · Jul 21 at 03:28 PM
16:26 ETERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
- Market Beat · Jul 20 at 03:29 AM
Erasca, Inc. (NASDAQ:ERAS) Receives Consensus Rating of "Moderate Buy" from Analysts
- prnewswire · Jul 17 at 09:46 PM
22:45 ETERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
